IP Library Patent Application 17384555
Patent Application
App. No. 17/384,555

METHODS OF USING OBETICHOLIC ACID

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/384,555
Abstract

The disclosure relates to methods of using obeticholic acid or pharmaceutically acceptable salt or amino acid conjugate thereof for slowing down or reversing the progression of compensated cirrhosis.

Claims (13)

1 . A method of treating compensated cirrhosis in a subject in need thereof comprising administering to the subject obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of 1-25 mg.

2 . The method of claim 1 , wherein the compensated cirrhosis is associated with NASH.

3 . The method of claim 1 , wherein the obeticholic acid is administered in the amount of 10 mg.

4 . The method of claim 1 , wherein the obeticholic acid is administered in the amount of 25 mg.

5 . A method of treating NASH in a subject with compensated cirrhosis due to NASH comprising administering to the subject obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of 1-25 mg.

6 . The method of claim 5 , wherein the obeticholic acid is administered in the amount of 10 mg.

7 . The method of claim 5 , wherein the obeticholic acid is administered in the amount of 25 mg.

8 . A method of treating liver fibrosis in a subject with compensated cirrhosis due to NASH comprising administering to the subject obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of 1-25 mg.

9 . The method of claim 8 , wherein the obeticholic acid is administered in the amount of 10 mg.

10 . The method of claim 8 , wherein the obeticholic acid is administered in the amount of 25 mg.

11 . The method of claim 1 , wherein the subject is not suffering from a cholestatic condition.

12 . The method of claim 5 , wherein the subject is not suffering from a cholestatic condition.

13 . The method of claim 8 , wherein the subject is not suffering from a cholestatic condition.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →